Waltham, MA-based Proteon Therapeutics has raised $15.2 million in financing, the Boston Business Journal reports, citing SEC documents. The new funding is in exchange for equity and options and follows the company's initiation of a mid-stage trial of its lead drug, PRT-201, which the firm says aims to "improve the outcomes associated with the surgical creation of vascular accesses in chronic kidney disease patients undergoing hemodialysis." Novartis ($NVS) has an option to acquire Proteon after the small firm completes Phase II development of the drug. Report